Short- versus long-duration levofloxacin plus rifampicin for acute staphylococcal prosthetic joint infection managed with implant retention: a randomised clinical trial


Por: Lora-Tamayo, J, Euba, G, Cobo, J, Horcajada, JP, Soriano, A, Sandoval, E, Pigrau, C, Benito, N, Falgueras, L, Palomino, J, del Toro, MD, Jover-Saenz, A, Iribarren, JA, Sanchez-Somolinos, M, Ramos, A, Fernandez-Sampedro, M, Riera, M, Baraia-Etxaburu, JM, Ariza, J

Publicada: 1 sep 2016
Resumen:
Levofloxacin plus rifampicin (L+R) is the treatment of choice for acute staphylococcal prosthetic joint infection (PJI) managed with debridement and implant retention (DAIR). Long courses have been empirically recommended, but some studies have suggested that shorter treatments could be as effective. Our aim was to prove that a short treatment schedule was non-inferior to the standard long schedule. An open-label, multicentre, randomised clinical trial (RCT) was performed. Patients with an early post-surgical or haematogenous staphylococcal PJI, managed with DAIR and initiated on L+R were randomised to receive 8 weeks of treatment (short schedule) versus a long schedule (3 months or 6 months for hip or knee prostheses, respectively). The primary endpoint was cure rate. From 175 eligible patients, 63 were included (52% women; median age, 72 years): 33 patients (52%) received the long schedule and 30 (48%) received the short schedule. There were no differences between the two groups except for a higher rate of polymicrobial infection in the long-schedule group (27% vs. 7%; P = 0.031). Median follow-up was 540 days. In the intention-to-treat analysis, cure rates were 58% and 73% in patients receiving the long and short schedules, respectively (difference -15.7%, 95% CI - 39.2% to 7.8%). Forty-four patients (70%) were evaluable per-protocol: cure rates were 95.0% and 91.7% for the long and short schedules, respectively (difference 3.3%, 95% CI -11.7% to 18.3%). This is the first RCT suggesting that 8 weeks of L+R could be non-inferior to longer standard treatments for acute staphylococcal PJI managed with DAIR. (C) 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Filiaciones:
Lora-Tamayo, J:
 Hosp Univ 12 Octubre, Inst Invest Hosp 12 Octubre I 12, Unidad Enfermedades Infecciosas, Madrid, Spain

Euba, G:
 Hosp Univ Bellvitge, Serv Enfermedades Infecciosas, Barcelona, Spain

Cobo, J:
 Hosp Univ Ramon & Cajal, Serv Enfermedades Infecciosas, IRYCIS, Madrid, Spain

Horcajada, JP:
 Hosp Mar, Serv Enfermedades Infecciosas, IMIM, CEXS UPF, Barcelona, Spain

Soriano, A:
 Hosp Clin Barcelona, Serv Enfermedades Infecciosas, IDIBAPS, Barcelona, Spain

Sandoval, E:
 Fdn Jimenez Diaz, Serv Traumatol, Madrid, Spain

Pigrau, C:
 Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Serv Enfermedades Infecciosas, Barcelona, Spain

Benito, N:
 Univ Autonoma Barcelona, Inst Invest Biomed St Pau, Hosp Santa Creu & St Pau, Unidad Enfermedades Infecciosas,Serv Med Interna, Barcelona, Spain

Falgueras, L:
 Corp Sanitaria Parc Tauli, Serv Enfermedades Infecciosas, Sabadell, Spain

Palomino, J:
 Hosp Univ Virgen de Rocio, Serv Enfermedades Infecciosas, Seville, Spain

del Toro, MD:
 Hospit Univ Virgen Macarena, Unidad Clin Interctr Enfermedades Infecciosas Mic, Seville, Spain

 Hospit Virgen de Rocio, Seville, Spain

Jover-Saenz, A:
 Hosp Arnau Vilanova, Unidad Func Infecc Nosocomial, Lleida, Spain

 Hosp Arnau Vilanova, Serv Med Interna, Lleida, Spain

Iribarren, JA:
 Hosp Univ Donostia, Serv Enfermedades Infecciosas, San Sebastian, Spain

Sanchez-Somolinos, M:
 Hosp Univ Gregorio Maranon, Serv Microbiol & Enfermedades Infecciosas, Madrid, Spain

Ramos, A:
 Hosp Univ Puerta de Hierro, Serv Med Interna, Unidad Enfermedades Infecciosas, Madrid, Spain

Fernandez-Sampedro, M:
 Hosp Univ Marques de Valdecilla, Serv Enfermedades Infecciosas, Santander, Spain

Riera, M:
 Hosp Univ Son Espases, Serv Med Interna, Unidad Enfermedades Infecciosas, Palma De Mallorca, Spain

Baraia-Etxaburu, JM:
 Hosp Univ Basurto, Serv Enfermedades Infecciosas, Bilbao, Spain

Ariza, J:
 Hosp Univ Bellvitge, Serv Enfermedades Infecciosas, Barcelona, Spain
ISSN: 09248579





INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Editorial
ELSEVIER, RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS, Países Bajos
Tipo de documento: Article
Volumen: 48 Número: 3
Páginas: 310-316
WOS Id: 000386022000012
ID de PubMed: 27524103

MÉTRICAS